Sodium Citrate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sodium Citrate: From Original Indication Not on File to Papillary Conjunctivitis
One-Sentence Summary
Sodium citrate’s original approved indication and mechanism of action are not recorded in the current evidence pack. The TxGNN model predicts potential efficacy for Papillary Conjunctivitis, but this is currently supported by 0 clinical trials and 0 publications — the prediction reflects only the AI model’s score, with no corroborating clinical or mechanistic evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no original indication recorded; MOA data not on file) |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.95% (rank 522) |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for sodium citrate is not available in this evidence pack, and no original approved indication is on file either. Sodium citrate is a citrate salt used in various pharmaceutical contexts, but without confirmed original-indication or MOA data here, no validated pharmacological link to the predicted new indication can be established.
For papillary conjunctivitis specifically, the evidence pack found no clinical trials and no published literature connecting sodium citrate to this condition, and no identifiable mechanistic relationship was found. The prediction rests solely on the TxGNN knowledge-graph model’s score (99.95%, ranked 522 out of all candidate diseases evaluated for this drug).
Because there is neither prior indication data nor mechanistic rationale to anchor the prediction, its biological plausibility cannot currently be assessed. This candidate would require independent mechanistic or preclinical investigation before it can be meaningfully evaluated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Sodium citrate currently has no SAHPRA registration on file (0 licenses) and its market status is Not Marketed in South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (papillary conjunctivitis) has zero clinical trial or literature support and no identifiable mechanistic link — evidence level L5 means this is a model-prediction-only signal. Combined with missing original-indication, MOA, and PI safety data (a Blocking-severity data gap), there is currently no basis to advance this candidate past initial screening.
To proceed, the following is needed:
- TFDA/SAHPRA-approved Professional Information (PI) for warnings, contraindications, and DDI data
- Confirmation of sodium citrate’s original approved indication(s) and mechanism of action
- Preclinical or mechanistic research establishing biological plausibility for papillary conjunctivitis
- Ongoing monitoring for emerging clinical trials or literature on this drug-disease pair
Note: Two other TxGNN-predicted indications for this drug — stomach disease (rank 4) and intestinal obstruction (rank 10) — reached evidence level L4/decision stage S1 with some supportive trial and literature signals, and may warrant separate evaluation as more promising leads than the top-ranked prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.